8-K: Eyenovia and Betaliq Announce Non-Binding Letter of Intent for Reverse Merger, Aiming to Create Leading Ophthalmic Company

Eyenovia and Betaliq have entered into a non-binding letter of intent for a reverse merger, seeking to combine their technologies and create a new publicly-listed eye care company.

Summary

• Eyenovia, Inc. and Betaliq, Inc. have entered into a non-binding letter of intent for a proposed business combination via a reverse merger.
• The merger aims to combine Betaliq's EyeSol water-free drug delivery technology for glaucoma with Eyenovia's Optejet device platform.
• The proposed transaction values Betaliq at approximately $77 million and Eyenovia at approximately $15 million, assuming zero net cash at closing.
• Upon closing, Betaliq equity holders are expected to own approximately 83.7% of the combined company, while Eyenovia equity holders would own approximately 16.3% on a fully diluted basis.
• Eyenovia expects to change its name to Betaliq, Inc. and change its trading symbol upon closing of the transaction.
• The exclusivity period for the deal ends on May 16, 2025, but is subject to extension.
• As of December 31, 2024, Eyenovia had approximately $2.1 million in cash.

Sentiment

Score: 6

Explanation: The announcement is a mix of positive and negative signals. The potential for a stronger combined company is positive, but the significant dilution for existing Eyenovia shareholders and the non-binding nature of the agreement temper the enthusiasm.

Positives

• The merger could create a leading ophthalmic company with a combined technology platform.
• The combination of EyeSol and Optejet technologies has the potential to improve the administration of topical eye medications.
• The combined company could continue marketing Eyenovia's existing FDA-approved products.
• Betaliq's EyeSol technology offers increased bioavailability and a small drop size, compatible with the Optejet device.
• The user-filled Optejet is on track for U.S. regulatory approval filing in the fourth quarter of this year.

Negatives

• The letter of intent is non-binding, and there is no assurance that a definitive agreement will be reached or that the merger will be completed.
• Eyenovia's existing equity holders will experience significant dilution, owning only approximately 16.3% of the combined company.
• The transaction is subject to various conditions, including due diligence, negotiation of definitive agreements, and financing contingencies.
• Eyenovia's valuation is significantly lower than Betaliq's in the proposed transaction ($15 million vs. $77 million).

Risks

• The proposed business combination may not be consummated on the terms described in the non-binding Letter of Intent or at all.
• Failure to enter into a definitive business combination agreement or consummate the proposed business combination could negatively affect Eyenovia's business, future business and financial results.
• Uncertainty about the effect of the proposed business combination on counterparties to contracts, employees, consultants, and other parties may have an adverse effect on Eyenovia and Betaliq.
• Eyenovia expects to incur substantial transaction costs in connection with the proposed business combination.
• There is a risk that Eyenovia's Common Stock may be delisted from Nasdaq.

Future Outlook

The combined company aims to leverage the synergies between EyeSol and Optejet technologies to create innovative treatment options for glaucoma and other ocular diseases, with potential for pipeline expansion through established partnerships.

Management Comments

• Michael Rowe, CEO of Eyenovia, stated that the merger with Betaliq is in the best interests of the company, team members, patients, and shareholders.
• Barry Butler, CEO of Betaliq, believes the merger represents a significant opportunity in the eyecare space and could bring innovative new treatment options to patients.

Industry Context

The merger reflects a trend in the pharmaceutical industry towards consolidation and the combination of complementary technologies to create more competitive and innovative products. The focus on glaucoma treatments aligns with the growing prevalence of the disease and the demand for improved therapies.

Comparison to Industry Standards

• Bausch + Lomb's MEIBO and Harrow's VEVYE, which utilize Betaliq's EyeSol technology, serve as benchmarks for the potential of this drug delivery system.
• The proposed merger aims to create a company that can compete with established players in the ophthalmic market by offering a unique combination of drug delivery and dispensing technologies.
• The success of the combined company will depend on its ability to effectively commercialize its products and secure regulatory approvals, similar to other companies in the pharmaceutical industry.

Stakeholder Impact

• Shareholders of Eyenovia will experience dilution but may benefit from the potential upside of the combined company.
• Employees of both companies may experience uncertainty regarding their roles and responsibilities during the transition period.
• Patients may benefit from the development of new and improved ophthalmic treatments.
• The merger could impact suppliers and partners of both companies as the combined entity integrates its operations.

Next Steps

• Completion of due diligence by both Eyenovia and Betaliq.
• Negotiation and execution of a definitive business combination agreement.
• Approval of the definitive agreement by the boards of directors of both companies.
• Completion of necessary financing contingencies.
• Seeking stockholder approval of the issuance of Eyenovia securities in excess of limits imposed by Nasdaq listing rules to the former Betaliq stockholders.

Key Dates

Keywords

reverse merger, Eyenovia, Betaliq, ophthalmic, EyeSol, Optejet, glaucoma, merger, acquisition